Rationale: Although the sodium channel locus SCN10A has been implicated by genome-wide association studies as a modulator of cardiac electrophysiology, the role of its gene product Nav1.8 as a modulator of cardiac ion currents is unknown.
T he opening of sodium channels initiates action potentials in most cardiac cells. The canonical cardiac sodium channel, Nav1.5, is encoded by SCN5A, and Nav1.5 blockers reduce sodium current (I Na ) in individual cells and conduction velocity in the heart. 1 The latter action can be antiarrhythmic but can also provoke arrhythmias, probably by engaging reentrant circuits. Mutations in SCN5A cause a range of human disease including type 3 long-QT syndrome characterized by defective fast inactivation, enhanced "late" sodium current (I Na-L ) during the plateau of the action potential, prolonged action potential duration (APD), and arrhythmogenic early afterdepolarizations (EADs). 2 
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The idea that sodium channels may not inactivate completely after opening was recognized in the node of Ranvier in the mid-1970s, 3 and a late plateau current in heart sensitive to the sodium channel specific toxin tetrodotoxin (TTX) was identified shortly thereafter. 4 -6 This late sodium current represents either channels that do not inactivate completely after opening or a "window" current flowing in the restricted voltage range where channels are activated and also not completely inactivated. The plateau current is sensitive not only to TTX but also to clinically used antiarrhythmics and other agents, [7] [8] [9] including the antianginal ranolazine 10 ; this effect of ranolazine is not specific for SCN5A channels, as the drug is known to block multiple other voltage-gated sodium channel isoforms. [11] [12] [13] The genome-wide association study (GWAS) paradigm has been used to examine variability in PR and QRS durations, electrocardiographic indices of atrioventricular and intraventricular conduction velocity, respectively. 14 -18 In both cases, the top associations have been with common single-nucleotide polymorphisms (SNPs) not in SCN5A, but in a directly adjacent gene, SCN10A, which encodes the Nav1.8 channel known to be expressed in dorsal root ganglia (DRG) 19, 20 and in retina, 21 but not previously implicated in cardiovascular function.
Preliminary studies 14 included in one of the PR GWAS reports detected expression of the gene by PCR in mouse and human heart and indicated shorter PR interval but no effect on QRS duration in Scn10a Ϫ/Ϫ mice. By contrast, the QRS meta-analysis reported 18 that the Nav1.8 blocker A-803467 22 prolonged both PR and QRS in wild-type mice and that the gene was expressed in heart and highly enriched in cells isolated from the conduction system. Notably, cells in the conduction system have the longest action potentials in the heart and a physiological I Na-L may contribute. 23, 24 Our findings demonstrate that Nav1.8 channels contribute to I Na-L in heart and that Nav1.8 block suppresses arrhythmogenic afterdepolarizations. These results not only reveal a direct role for Scn10a expression in cardiac electrophysiology but also identify its gene product as a potential target for antiarrhythmic intervention.
Methods

FuGENE6-Mediated Channel Expression and Cell Transfection
ND7/23 cells (Sigma-Aldrich, St Louis, MO), a cell line formed by fusion between mouse neuroblastoma and rat DRG cells, 25 were cultured in Dulbecco modified Eagle's medium (DMEM, Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (Invitrogen), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin at 37°C under 95% airϩ5% CO 2 . After growth to Ϸ70% confluence on 35-mm polystyrene culture dishes in culture, cells were transiently transfected as follows: 2 to 3 g of the cDNA encoding human SCN10A or SCN5A (plus 0.5 g of a plasmid for green fluorescent protein, GFP) were mixed with 10 L FuGENE6 (Roche) in 0.5 mL serum-free DMEM medium and incubated for 30 minutes, after which the standard medium was replaced for a 48-hour incubation. GFP was used as a marker to identify successfully transfected cells for the electrophysiology studies. The cells were harvested by brief wash-off without trypsinization and stored in standard medium for use within 12 hours.
Isolation of Mouse and Rabbit Ventricular Cardiomyocytes
Adult mouse and rabbit cardiac ventricular myocytes were isolated by a modified collagenase/protease method (Online Data Supplement Methods) 26 ; in these studies, we used mice in which the murine gene has been ablated and the human cardiac sodium (H) channel gene has been placed in the murine Scn5a locus. 27 We have previously shown that these H/H mice display sodium current and electrocardiograms identical to those from wild-type mice. 27 All procedures were approved by the Institutional Animal Care and Use Committee. For electrophysiology experiments, mice (12 wild-type and 3 Scn10a Ϫ/Ϫ ) and rabbits (nϭ5) were used.
Ion Current Recordings
The biophysical properties of sodium currents were determined by voltage-clamp protocols shown in the Figures. Voltage dependence of inactivation was studied using 500-ms prepulses from Ϫ120 to Ϫ20 mV in 10-mV increments, followed by a 100-ms test pulse to ϩ20 mV (for the Nav1.8 channel) or Ϫ20 mV (for the Nav1.5 channel). Two types of voltage-clamp experiments were conducted. First, we applied regular 200-ms square-wave pulses to record peak and late I Na in mouse or rabbit ventricular myocytes before and during drug application. The second protocol was a slow ramp to specifically examine late current without the need for a previously depolarizing pulse; this approach allows the experiment to be conducted in physiological extracellular sodium concentration. In both instances, the perfusate contained 1 mol/L nisoldipine and 200 mol/L NiCl 2 to block other inward current through L-and T-type calcium channels.
Current-voltage relations for steady-state activation and inactivation were determined by fitting a Boltzmann function (I/ Imaxϭ[1ϩexp((VϪV 1/2 )/k)] Ϫ1 ), yielding the membrane potential of the half-maximal activation (V 1/2 -activation) and inactivation (V 1/2inactivation) and slope factor (k). The time course of inactivation of macroscopic current was fit with a monoexponential Chebyshev equation: IϭA 1 *exp[Ϫ(t-k)/r 1 ]ϩC.
Action Potential Recordings
To record action potentials from isolated ventricular myocytes, cells were studied in current-clamp mode (Axopatch 200B amplifier, Molecular Diagnostics, Sunnyvale, CA) by injecting stimulus current (1-2 nA, 2-4 ms) at different frequencies (5, 2, 1, and 0.1 Hz). Junction potentials between pipette and bath solutions were compensated electronically.
Data acquisition was carried out using an Axopatch 200B patchclamp amplifier and software pCLAMP 9.2. Currents were filtered at 5 kHz (Ϫ3 dB, 4-pole Bessel filter) and digitized using an analogto-digital interface (Digidata 1322A, Molecular Diagnostics). To minimize capacitive transients, capacitance was compensated Ϸ80%. Series resistance was 1 to 4 mol/L⍀. In all voltage-clamp experiments, the protocols are presented schematically in the Figures . Linear leakage currents were digitally subtracted online by the P/N protocol. All ion currents and action potential (AP) parameters were analyzed using pCLAMP9.2 software.
RNA Isolation and Real-Time PCR
An expanded Methods section is available in the Online Data Supplement.
Solutions and Drugs
To record Nav1.8 and Nav1.5 currents transiently expressed in ND7/23 cells, we used an external K ϩ -free solution that contained (in mmol/L): 135 NaCl, 1.8 CaCl 2 , MgCl 2 1.0, TEA-Cl, 10 HEPES, and 10 glucose, with a pH of 7.4 adjusted with NaOH. Endogenous TTX-sensitive I Na and L-/T-type I Ca were eliminated with tetrodotoxin 200 nmol/L, nisoldipine 0.5 mol/L, and NiCl 2 200 mol/L, respectively. Glass electrodes were filled with the internal solution that contained (in mmol/L): 120 CsF, 10 NaCl, 1 CaCl 2 , 1 MgCl 2 , 10 EGTA, 10 TEA-Cl and 10 HEPES, with a pH of 7.3 adjusted with CsOH. To better control I Na recording in mouse and rabbit ventricular myocytes, the internal and external Na ϩ concentrations were lowered to 5 and 20 mmol/L, respectively. The experiments for I Na recordings in myocytes were conducted at 18°C. Other experiments were done at 22Ϸ23°C.
To record the action potentials in mouse and rabbit ventricular myocytes, external Tyrode solution contained (in mmol/L): 135 NaCl, 4 KCl, 1.8 CaCl 2 , and 1 MgCl 2, 5 HEPES, and glucose 10, with a pH of 7.4 (adjusted by NaOH). The pipette (intracellular) solution had (in mmol/L): 120 Aspirate-K, 25 KCl, 4 ATP-Na 2 , 1 28 to make a stock solution of 1 mmol/L. During the experiments, the drug solution was further diluted at the desired test concentrations. The final concentrations of solvents in the cell chamber were 0.01% or less, with no effects on Nav1.8 and action potentials in separate experiments. For experiments in which the antiarrhythmic effect of Nav1.8 block was examined, the external Tyrode solution with lower external potassium (2 mmol/L), and a low concentration of ATX-II (3-5 nmol/L) was used to induce EADs. Experiments evaluating the effects of drug were conducted by first establishing a predrug stable baseline and then adding drug to the extracellular solution until a new steady state was evident during repetitive pulsing.
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Generation of Scn10a ؊/؊ Mice
Founder mice were regenerated by MRC Harwell, using the same construct as previously reported. 29 Mice were genotyped using PCR amplification of fragment that includes the targeted region: a 1100-bp band was seen in wild-type mice and a 900-bp band in the Scn10a Ϫ/Ϫ mice. Ventricular myocytes were isolated and studied using the same procedures as those outlined above.
Statistical Analysis
Results are presented as meanϮSEM, and statistical comparisons were made using the unpaired and paired Student t test. A value of PϽ0.05 was considered statistically significant. Statistical significance for quantitative real-time PCR was determined by the Wilcoxon rank-sum test.
Results
Contrasting Electrophysiological and Pharmacological Properties of Nav1.8 and Nav1.5 in a Heterologous Expression System
As previously reported, 30 expression of SCN10A in CHO or HEK cells, heterologous systems conventionally used to study SCN5A, yielded very small and inconsistent currents, even with coexpression of any of the 4 sodium channel ␤-subunits or incubation at low temperatures. However, in ND7/23 cells (a cell line formed by fusion between mouse neuroblastoma and rat DRG cells), robust currents were readily detected. 28 We confirmed expression of the construct and the absence of any endogenous SCN10A by RT-PCR (Online Figure I) . These cells do express a TTX-sensitive channel so all the experiments reported here were conducted in the presence of a low concentration (200 nmol/L) of TTX. Both Nav1.5 and Nav1.8 are designated TTX-resistant because a high concentration (30 mol/L) is required to suppress Nav1.5 current and does not affect Nav1.8 currents.
In addition, the cells express both ␤1 and ␤3 sodium channel subunits. 25 Figure 1 shows currents recorded with transfection of SCN10A or SCN5A in ND7/23 cells. The SCN5A-mediated current displays fast activation and inactivation typical for Nav1.5 current (and shown in Figure 1A ) recorded in other cells transfected with SCN5A plus SCN1B, encoding the ␤1 subunit. By contrast, SCN10A-mediated current activates and The voltage-clamp protocol is shown in the inset. B, Nav1.5 recorded in SCN5Atransfected ND7/23 cells. The similarity between currents in B and A support previous reports that ND7/23 cells express endogenous ␤1 and ␤3 subunits. C, Nav1.8 recorded in SCN10A-transfected ND7/23 cells. Nav1.8 activates and inactivates much more slowly than does Nav1.5. D, Current-voltage curves showing that SCN10A current activates at much more positive potentials than does SCN5A current. E, Voltage dependence of activation and inactivation of Nav1.8 and Nav1.5 in ND7/23 cells. In SCN10A channels, the area of overlap (dotted box) under the activation and inactivation curves is much larger than that for SCN5A, suggesting that SCN10A channels generate an increased "window" current; nϭ6 for SCN5A and nϭ9 for SCN10A.
inactivates much more slowly. Online Table I contrasts the Nav1.5 and Nav1.8 currents in ND7/23 cells. Not only is the time to peak Nav1.8 current strikingly delayed compared with that for Nav1.5, but the postpeak (late) current also represents a much larger fraction of peak current than with Nav1.5. In addition, Nav1.8 channels activate at much more positive potentials than do Nav1.5 channels; the peak current amplitudes were at Ϸϩ20mV compared with ϷϪ30 mV for Nav1.5. Both channels displayed an overlap of activation and inactivation voltage relationships that would enable a "window" current, but in different voltage ranges ( Figure 1E) . Figure 2A and 2B show the selectivity of the blocker A-803467 for Nav1.8 over Nav1.5 currents in this system. Single 50-ms repetitive pulses from Ϫ120 mV to ϩ20 mV (the potential at which peak Nav1.8 current is observed) were used to elicit Nav1.8 current, and block was near-complete with 30 nmol/L A-803467 ( Figure 2A ). However, this concentration of drug produced no effect on Nav1.5 current studied with single pulses to Ϫ30 mV (the potential at which peak Nav1.5 current is recorded). Indeed, even at 1000 nmol/L, the blocker had minimal effect on Nav1.5 current ( Figure 2B ). No effect of A-803467 on peak sodium current was also seen in mouse cardiomyocytes (Online Figure IIA) .
As described below, experiments using A-803467 in cardiomyocytes implicated Scn10a as a mediator of late I Na . However, late I Na is commonly more sensitive to drug block than is peak I Na . Accordingly, we conducted further experiments to examine the effects of A-803467 on physiological and pathologically increased Nav1.5-mediated late current. Figure 2C shows that in ND7/23 cells, application of the sodium channel opener ATX-II augments Nav1.5-mediated sodium current but that this augmented current is not highly sensitive to A-803467: ATX-augmented SCN5A-mediated late current was no more sensitive to A-803467 than was peak current (50% block at Ϸ5000 nmol/L). Another setting in which SCN5A-mediated late current is pathologically enhanced is in type 3 long-QT syndrome. Figure 2D shows that 1000 nmol/L A-803467 had no effect on late currents recorded with heterologous expression of LQT3 mutant SCN5A channel F1486L; the same lack of effect on LQT3 late current was observed with the mutants R1544H and -803467 on Nav1.5 current in an SCN5Atranfected ND7/23 cell. C, Late current was first elicited by 100 nmol/L ATX-II in an SCN5A-transfected ND7/23 cell the effect of increasing concentrations of A-803467 were then examined; the IC 50 was Ϸ5000 nmol/L. Under the same conditions, the IC 50 for block of late SCN10A currents was Ϸ10 nmol/L. D, The LQT3 mutant F1486L generated a large late I Na in CHO cells, and this was unaffected by 1000 nmol/L A-803467. The same lack of effect was seen with late I Na generated by R1544H and T1304 mol/L (data not shown).
T1304. This blocker at high concentrations (1 and 10 mol/L) also had minor effect on L-type calcium current in mouse myocytes (Online Figure IIB) .
We also examined the relative abundance of Scn10a transcripts in mouse heart compared with those for human cardiac sodium channel allele by quantitative RT-PCR ( Figure 3 ). Scn10a transcripts are readily detected in both atria and right ventricle but were markedly reduced in left ventricle. The ND7/23 cell data and the expression data establish low-dose A-803467 as a tool to dissect the contribution of Scn10a to ionic currents recorded in cardiomyocytes. Figure 4A shows the effects of A-803467 (30 nmol/L) on peak and late sodium current in mouse ventricular myocytes. The right-hand panels contrast, at expanded scales, the prominent suppression of late current with minimal effects on peak current; late currents such as these were observed in approximately half of the cells studied. A 2-second voltage command ramp from Ϫ120 mV to ϩ40 mV ( Figure 4B ) elicited an inward current with 2 minima, one at ϷϪ70 mV and the second at ϷϪ10 mV. A-803467 reduced the component at the more positive potential, and the A-803467 sensitive-current obtained by digital subtraction is shown as difference current. Data summarizing the effect of A-803467 on these 2 minima in the ramp current are presented in Figure  4C and 4D; the drug reduced current at Ϫ70 mV by 7.3Ϯ1.3% and at 0 mV by 39.2Ϯ6.2% (nϭ8, PϽ0.01). These data further confirm that Nav1.8 current contributes to late sodium current (I Na-L ) in heart. 
A Component of Sodium Current in Cardiomyocytes Is Sensitive to Low Concentrations of A-803467
A-803467 Shortens Ventricular APD and Suppresses EADs
. Effect of A-803467 on sodium current (I Na ) in mouse ventricular myocytes. A, Sodium current traces elicited by repetitive
200-ms square pulses from Ϫ120 mV to 0 mV in a ventricular myocyte in the absence (solid traces) and presence (dotted traces) of the blocker; current is normalized as I/I max (%), where I max is peak inward current before drug. A, Right panels highlight at expanded scales the effect of the drug to selectively and near-completely inhibit late current but to exert minimal effect on peak sodium current, consistent with the idea that peak current represents predominantly SCN5A current. B, Using a ramp protocol reveals that the drug prominently blocked late current at more positive potentials. The A-803467-sensitive current was obtained by digital subtraction. C, Summary data for ramp experiments show the effects of the drug on the ramp currents at Ϫ70 and 0 mV (nϭ8). D, Preferential suppression of the late current at 0 mV by the drug. ones, action potential shortening was evident (right, Figure  5A ). The effects on APD at 50% and 90% repolarization (APD 50 and APD 90 ) in individual cells (nϭ20) are shown in Figure 5B through 5E: these differences are statistically significant at slower rate, although no effect by A-803467 was observed in 9 of 20 cells. This is consistent with the notion that I Na-L is a more prominent contributor to action potential duration at slow rather than at fast rates and that not all ventricular myocytes express Scn10a. Figure 6 shows the results of experiments conducted in rabbit myocytes. As in mouse cells, 30 nmol/L A-803467 preferably inhibited late current during 200-ms pulsing and had only a minor effect on peak current in rabbit cardiomyocytes. The drug-sensitive component (as difference current) was separated from the mixed sodium currents by digital subtraction (Figure 6A and insets) . The difference current displays very slow activation and inactivation with prominent late current, features similar to those seen with heterologous expression of SCN10A in ND7/23 cells. Figure 6B shows action potential traces in a rabbit ventricular myocyte recorded at 2 Hz before and during exposure to 30 nmol/L A-803467, which shortened APD. The effect on APD 50 and APD 90 in 7 rabbit myocytes are summarized in Figure 6C .
The action potential prolongation generated by enhanced I Na-L can generate EADs that have been implicated in arrhythmias in both congenital long-QT syndromes 31 and in acquired settings. 32, 33 We exposed myocytes to a low concentration of ATX-II and then demonstrated that 30 nmol/L A-803467 suppressed EADs elicited under these conditions in mouse and rabbit myocytes. Figure 7A shows action potentials in a mouse myocyte recorded under EAD-promoting conditions: low extracellular potassium (2 mmol/L) and exposure to a low concentration (3 nmol/L) of the sodium channel opener ATX-II. Using 1-Hz stimulation rate under these conditions elicited EADs and triggered activity ( Figure 7B through 7D), and these abnormal action potentials were promptly suppressed by 30 nmol/L A-803467. This effect was observed in 7 of 8 mouse preparations.
Very similar effects were observed in rabbit myocytes ( Figure 7G through 7I) . Exposure to 5 nmol/L ATX-II for 15 minutes induced EADs that lasted longer than the drive cycle length ( Figure 7H ). When the cell was pretreated with A-803467 for 15 minutes, addition of 5 nmol/L ATX-II did not cause long-lasting EADs, although the recorded action potentials still were much longer than that in control (indicated by an arrow in Figure 7I ). Figure 8 shows that in ventricular myocytes isolated from Scn10a Ϫ/Ϫ mice, no late sodium current was recorded and there was no effect of 30 nmol/L A-803467 on current recorded at the peak or at 200 ms after the onset of the depolarizing pulse. Action potentials were shorter than those in wild-type animals, and there was similarly no effect of A-803467 on APD.
Effects of A-803467 in Scn10a ؊/؊ Mouse Cardiomyocytes
Discussion
One of the key scientific advances enabled by the GWAS paradigm is the identification of genes and pathways contributing to important human phenotypes and not previously implicated in human physiology. 34 GWAS provides a very robust and reproducible signal that variation at the SCN10A locus, not previously implicated in cardiac physiology, modulates conduction in the heart. However, a function of the SCN10A gene product Nav1.8 in cardiac electrophysiology had not, to date, been defined. We used the Nav1.8-specific blocker A-803467 to not only define a role of Nav1.8 channels in control of the cardiac action potential but also to demonstrate that block of Nav1.8-mediated current can exert antiarrhythmic actions.
One hurdle that we had to overcome in these experiments was to identify and validate a system to compare Nav1.5 and Nav1.8 pharmacology. Cell lines that routinely generate Figure 6 . Effects of A-803467 on late current and action potential duration in rabbit ventricular myocytes. A, Sodium current traces elicited by repetitive 200-ms square pulses from Ϫ120 mV to 0 mV in a ventricular myocyte in the absence and presence of the blocker; the current component blocked by A-803467 is indicated by difference current obtained by digitally subtracting the currents before and after drug. A, Right side highlights at expanded scale the effect of the drug to selectively inhibit late current with a slowly activating and slowly inactivating difference current and minimal effect on peak sodium current, consistent with the idea that peak current represents predominantly Nav1.5 current. Insets are presented as percentages after normalization to peak sodium current. B, Action potential traces recorded with repetitive stimulation at 2 Hz before drug (top) and during exposure to 30 nmol/L A-803467 (bottom). C, Summary of action potential durations (APD 50 and APD 90 ) in the absence and presence of A-803467.
robust Nav1.5 currents with transfection did not generate similar Nav1.8 currents. The likely explanation for this finding is that ND7/23 cells express some key but as yet unidentified cofactor necessary for Nav1.8 expression and absent from HEK or CHO cells. The major findings in the ND7/23 experiments we present are that A-803467 is specific for Nav1.8 over Nav1.5 and that the channels display striking differences in gating and late current.
Although our findings demonstrate a role for Nav1.8 in the control of cardiac repolarization as assessed by action potential duration, the GWAS results implicate variants in SCN10A as modulators of cardiac conduction. The functional characteristics of Nav1.8 current in the heterologous expression experiments indicate that the current activates much more slowly than does Nav1.5 current, and this difference may in turn contribute to variable cell-to-cell charge transfer that underlies fast conduction in heart. Available data raise the possibility that the SCN10A signal may be mediated by a nonsynonymous coding region SNP, resulting in V1073A. Preliminary reports indicate V1073A does demonstrate gating characteristics that differ from the wild-type channel, 35 but these experiments have only been conducted in heterologous expression systems and so the way in which this variant modulates Nav1.8 function awaits further studies in myocytes.
The quantitative RT-PCR data unexpectedly show that Scn10a expression is much higher in right compared with left ventricle. It is conceivable that this signal reflects enrichment in specialized cell types (eg, conduction tissue). Indeed, the QRS GWAS report included data that expression was enriched in mouse cardiac Purkinje cells compared with ventricle 18 ; Purkinje cells have longer action potentials than those in ventricle, so it is conceivable that Nav1.8 contributes to this difference. We only observed a late current sensitive to 30 nmol/L A-803467 in about half of the myocytes we studied, consistent with the idea that many myocytes will lack Nav1.8 expression. In the electrophysiological experiments, we did not distinguish myocytes of left versus right ventricular origin.
Interestingly, whereas Nav1.5 is the canonical cardiac sodium channel, other channels are known to be expressed at lower levels and in specific regions in heart. 36, 37 One report indicates that Nav1.8 is detectible in heart and pericardiac ganglia by immunostaining, 38 but, using Western analyses, we have been unable to establish the specificity of any commercially available antibody. Thus, a key unanswered question is the cellular and subcellular localization of the Nav1.8 channel in heart and other tissues. The possibility remains, for example, that the GWAS conduction velocity signal reflects neural modulation of cardiac conduction by Nav1.8 channels expressed in cardiac ganglia. Further, our data ( Figure 5B through 5E) indicate that the extent to which A-803467 shortens action potential duration varies from cell to cell, suggesting that the current plays a variable role, perhaps across cell subtypes, in cardiac repolarization. The qRT-PCR data demonstrate that there is striking variability in the detection of Scn10a transcripts across chambers but do not address cell-type specific expression of the gene.
A low concentration of A-803467 suppressed EADs and associated triggered activity. ATX-II interferes with inactivation of multiple sodium channel isoforms, including Scn5a. However, the antiarrhythmic effect of A-803467 cannot be attributed to block of Nav1.5 channels because we have shown that the concentration used is far below that required to even minimally block physiological or pathological late Nav1.5 current. Thus, we infer that the effect of A-803467 in this setting is to eliminate a component of arrhythmogenic inward current-presumably mediated by Nav1.8 -to a sufficient extent to suppress EADs and triggering. The failure of A-803467 to alter APD in multiple ventricular myocytes from Scn10a Ϫ/Ϫ mice lends further support to this hypothesis.
The demonstration that Nav1.8 channels play a role in cardiac repolarization and that Nav1.8 block can suppress arrhythmogenic EADs represents a key proof-of-principle finding for further development of this novel antiarrhythmic strategy. Many currently available antiarrhythmics block both peak and late current mediated by Nav1.5, 7,8 but these can provoke arrhythmias. 39 Ranolazine appears to be more selective for late current, 10 and, to date, less proarrhythmic. 40, 41 Indeed, ranolazine exerts antiarrhythmic effects in some settings, 42-44 including suppressing EADs. However, the drug is not selective for Nav1.5 currents. The interesting difference between Nav1.5 and Nav1.8 activation raises the possibility that selective block of late Nav1.8-mediated current could be antiarrhythmic without proarrhythmic liability. current at 0 mV, with a minor reduction of peak current. D, Normalized sodium current traces recorded at 0 mV from 2 separate myocytes from WT and Scn10a Ϫ/Ϫ mice. Difference current is a component obtained by digital subtraction of these two traces. This difference current resembles the Nav1.8 current seen in Figure 1C and A-803467 sensitive current in Figure 6A . E, In same Scn10a Ϫ/Ϫ myocyte, adding 30 nmol/L A-803467 had no effect on sodium current. F, Individual and summarized late current data after normalization to cell size (in pA/pF) in individual myocytes studied before and during exposure to 30 nmol/L A-803467. Solid circles represent the mean value (ϮSEM) for each group. 
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Novelty and Significance
What Is Known?
• Genome-wide association studies have implicated variation in the sodium channel gene SCN10A as modulators of cardiac conduction (PR and QRS durations). • SCN10A was originally cloned from dorsal root ganglion, and the encoded channel (termed Nav1.8) is thought to play a role in pain perception.
What New Information Does This Article Contribute?
• A specific Nav1.8 blocker eliminates the persistent sodium current recorded after long depolarizing pulses in mouse and rabbit cardiomyocytes and shortens the action potential duration. • These effects are absent in myocytes from Scn10a knockout mice. • The Nav1.8 blocker reverses arrhythmogenic early afterdepolarizations elicited by experimental conditions that increase persistent sodium current.
Genome-wide association studies of cardiac conduction suggest a role for variation in SCN10A, not previously implicated in heart function. We show that Scn10a transcripts are present in the mouse heart. Also, we confirmed the selectivity of the Nav1.8 blocker A-803467 over Nav1.5 encoded by the canonical cardiac sodium channel gene SCN5A. In mouse and rabbit ventricular myocytes, a low concentration of A-803467 had little effect on peak sodium current but eliminated "late" current recorded after a long depolarizing pulse and shortened action potential duration. These effects were absent in cells from Scn10a knockout mice. The blocker also eliminated arrhythmogenic early afterdepolarizations elicited when the late current was increased. These results identify a role for the SCN10A gene product in mediating late current in the heart and suggest that inhibition of this current may be antiarrhythmic under some conditions.
